Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Novartis restarts production of radioligand therapy

By Sean Whooley | July 21, 2022

Novartis logoNovartis announced recently that it has restarted radioligand therapy (RLT) production at two different sites.

Basel, Switzerland-based Novartis on June 30 said that it restarted production in “early June” at its Ivrea, Italy, and Millburn, New Jersey, sites, according to a news release. The company had halted production in May due to what it cited as potential quality issues in its manufacturing processes.

Radioligand therapy harnesses the power of radioactive atoms and applies it to advanced cancers to deliver radiation to target cells anywhere in the body with the aim of limiting damage to surrounding tissues through a targeted approach. Radioligands are also used in positron emission tomography.

The company also resumed delivery of doses to patients in a phased approach ahead of its expected six-week timeframe.

“The company has remediated the issues that led to the temporary, voluntary suspension of production in May,” Novartis wrote in the release. “These issues did not affect patient safety, and no risk to patients from the doses previously produced at these sites was identified.”

Novartis has also restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 (INN: lutetium (177Lu) vipivotide tetraxetan), marketed as Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in the U.S., in most countries globally, and clinical trials with Lutathera (USAN: lutetium Lu 177 dotatate; INN: lutetium (177Lu) oxodotreotide) in the U.S. and Canada.

Additionally, the company said it will invest in the expansion of RLT production capabilities at both the Italy and New Jersey locations to support the growing demand for its RLT platform. It also intends to build a new radioligand manufacturing facility in Indianapolis, Indiana, that will be operational in 2023.

“We recognize that this situation has affected – and is still affecting – patients, their families and care teams,” Novartis said. “Product quality and patient safety remain the company’s top priorities. We expect that product supply may be initially limited, and we are working hard to resume full production capacity and meet patient demand as quickly as possible.

“We continue to communicate with health authorities, and they are aware that we have restarted production and that the delivery of patient doses has resumed.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

GSK
GSK finalizes Affinivax acquisition 
vaccine
U.S. government makes an additional 442,000 monkeypox vaccine doses available 
Biogen logo
Biogen is scaling back space outside Boston
Fresenius Kabi
Fresenius Kabi plans to add 2D barcodes to its pharmaceutical portfolio

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards